GlassScriptPhysician profile
Julisa Rosa
NPI 1295107480
$4,721.08
in general payments reported to CMS, 2019-2025
22 companies · $1,191 in 2025
The $1,191 reported for 2025 was more than what 89% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,003 · 2022: $742 · 2023: $1,016 · 2024: $770 · 2025: $1,191.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,957 · Education: $19.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,956.94 |
| Education | $19.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,298.94 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $766.07 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $417.88 | 2021-2025 | |
| Exact Sciences Corporation | $354.65 | 2023-2025 | Cologuard Collection Kit |
| Lilly USA, LLC | $335.18 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Currax Pharmaceuticals LLC | $269.56 | 2021-2025 | Contrave, Onzetra Xsail |
| Pfizer INC. | $208.24 | 2021-2025 | |
| Amarin Pharma, INC. | $150.49 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $132.64 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $130.55 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $125.88 | 2021-2024 | Jardiance |
| Glaxosmithkline, LLC. | $98.67 | 2021-2023 | Shingrix, Trelegy Ellipta, Arexvy |
| Amgen INC. | $94.60 | 2023-2024 | Otezla, Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $89.62 | 2022 | |
| Ars Pharmaceuticals Operations, INC. | $52.22 | 2025 | Neffy |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $51.58 | 2021-2025 | Tirosint, Licart, Flector |
| Abbott Laboratories | $45.46 | 2023 | Proclaim |
| Optinose US, INC. | $23.48 | 2025 | |
| Linus Health, INC. | $23.08 | 2022 | |
| Amneal Pharmaceuticals LLC | $20.10 | 2025 | Unithroid |
| Phadia US INC. | $18.44 | 2023 | Immunocap |
| Lucid Diagnostics INC. | $13.75 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julisa Rosa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.